ViewRay

ViewRay, Inc. designs, manufactures and markets magnetic resonance imaging (MRI) system. It develops MRIdian to address the limitations of existing external-beam radiation therapy technologies, and employs MRI-based technology to provide real-time imaging that defines the tumor from the surrounding soft tissue, and other critical organs, both before and during radiation treatment delivery. The company was founded by Dinara Akzhigitova in 2004 and is headquartered in Oakwood Village, OH.

Earnings data Q1 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ViewRay, Inc. designs, manufactures, and markets the MRIdian MRI-guided Radiation Therapy System. It develops MRIdian to address the limitations of existing external-beam radiation therapy technologies and employs MRI-based technology to provide real-time imaging that defines the tumor from the surrounding soft tissue, and other critical organs, both before and during radiation treatment delivery. The company was founded by Dinara Akzhigitova in 2004 and is headquartered in Oakwood Village, OH.

CLEVELAND, Oct. 18, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the company will host a Virtual Clinical Data Event for Investors and Analysts on Thursday, October 28, 2021. The event will begin at 8:30 am ET / 5:30 am PT.

ViewRay to Host a Virtual Clinical Data Event for Investors and Analysts on October 28, 2021

CLEVELAND, Oct. 14, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its third quarter 2021 financial results. ViewRay will hold a conference call to discuss results on Thursday, November 4, 2021 at 4:30 p.m.

ViewRay Announces Conference Call for Third Quarter 2021 Financial Results to be Held After Market on November 4, 2021

CLEVELAND, Sept. 29, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the company has received acceptance from the FDA on their recent submission for new MRIdian features focused on enhancing on-table adaptive workflow efficiency and expanding clinical utility.

ViewRay Announces 510(k) Pending Status of the Newest Generation of MRIdian Innovations

CLEVELAND, Sept. 16, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that the Company will participate in the Cantor Global Healthcare Conference.

ViewRay® to Partcipate in the Cantor Global Healthcare Conference

CLEVELAND, Aug. 27, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that the Company will present at the Morgan Stanley 19th Annual Global Healthcare Conference. Scott Drake, President and Chief Executive Officer, and Zach Stassen, Chief Financial Officer, will participate in a fireside chat at 10:15 a.m.

ViewRay® to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

CLEVELAND, Aug. 24, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the clinical team at Amsterdam University Medical Centers (Amsterdam UMC) has started offering "same-day ablative treatment" using MRIdian SMART (stereotactic MR-guided adaptive radiotherapy) for patients who are eligible for single fraction MRI-guided radiation therapy. Three patients under treatment for lung tumors were the first to benefit from this program.

Amsterdam University Medical Centers establishes same-day ablative treatment service using MRIdian® to Streamline the Patient Experience.

CLEVELAND, Aug. 17, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that UCLA Health joins the Siteman Cancer Center at Washington University, Seoul National University Hospital and Amsterdam UMC in surpassing the treatment of 1,000 patients using the MRIdian® MRI-guided radiation therapy system. UCLA Health is the fourth MRIdian center to reach this treatment milestone in bringing the benefits of MRI-guided radiation therapy to cancer patients.

UCLA Health Treats its 1,000th Patient Using MRIdian® MRI-Guided Radiation Therapy

ViewRay, Inc. (VRAY) CEO Scott Drake on Q2 2021 Results - Earnings Call Transcript

Investors didn't like the company's Q2 update.

Why ViewRay Stock Is Sinking Today

CLEVELAND, Aug. 5, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the second quarter ended June 30, 2021. Second Quarter 2021 Highlights Received seven new orders for MRIdian systems totaling $37.9 million, compared to four new orders totaling $24.6 million in the second quarter of 2020.

ViewRay Reports Second Quarter 2021 Results

CLEVELAND, July 15, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its second quarter 2021 financial results. ViewRay will hold a conference call to discuss results on Thursday, August 5, 2021 at 4:30 p.m.

ViewRay Announces Conference Call for Second Quarter 2021 Financial Results to be Held After Market on August 5, 2021

CLEVELAND, July 7, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the Miami Cancer Institute, part of Baptist Health South Florida, has enrolled the first patients in its "Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) in One Fraction for Inoperable Primary or Metastatic Carcinoma" clinical study – referred to as the SMART ONE trial (NCT#04939246). This single-arm prospective study that was developed and led by Dr. Michael Chuong, MD, FACRO, radiation oncologist and Medical Director of Proton Therapy and MR-guided Therapy at Miami Cancer Institute, is exploring the feasibility and tolerability of single-fraction stereotactic ablative body radiation therapy (SABR) for primary or metastatic carcinoma involving the lung, liver, adrenal gland, abdominal/pelvic lymph node, pancreas, and kidney.

Miami Cancer Institute Enrolls First Patients in Single-Fraction Stereotactic MRI-Guided Adaptive Radiation Therapy for Inoperable Primary or Metastatic Cancer Trial

ViewRay (VRAY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

ViewRay (VRAY) Stock Jumps 11.7%: Will It Continue to Soar?

The company announced an exciting new deal with a major specialist company from Down Under.

Why ViewRay Crushed the Market on Thursday

Master agreement includes program plans for up to a further 14 systems with immediate expansion in 2 key markets CLEVELAND, June 24, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that GenesisCare has entered into a master purchase agreement for up to 14 MRIdian® MR-Guided Therapy Systems, immediately expanding programs in United Kingdom (UK) and Ft. Myers, Florida.

GenesisCare Expands their MR-guided Radiotherapy Reach with the Purchase of Multiple MRIdian® Systems

FORT MYERS, Fla., June 24, 2021 /PRNewswire/ -- GenesisCare—one of the leading oncology providers in the United States, Australia, Spain, and the United Kingdom—today announced it expanded its partnership with ViewRay, Inc. (NASDAQ: VRAY) by purchasing new MRIdian® MR-Guided Therapy Systems to offer personalized and precise radiation therapy.

Cancer Patients Across the U.S. to Benefit from GenesisCare's Partnership with ViewRay, Inc.

CLEVELAND, May 25, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that American Hospital in Istanbul, Turkey, has purchased a MRIdian MRI-guided radiation therapy system to expand their radiotherapy and stereotactic body radiation therapy (SBRT) programs. The MD Anderson Radiation Treatment Center at the American Hospital offers world-class, cutting-edge technology to facilitate customized approaches to each patient's diagnosis and treatment.

American Hospital in Istanbul, Turkey Purchases MRIdian® MRI-Guided Radiation Therapy System

CLEVELAND, May 17, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that the Company will present at the Jefferies 2021 Virtual Healthcare Conference. Scott Drake, President and CEO, and Zach Stassen, CFO, will participate in a fireside chat at 11:00 a.m.

ViewRay® to Present at the Jefferies 2021 Virtual Healthcare Conference

ViewRay (VRAY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Strength Seen in ViewRay (VRAY): Can Its 13.8% Jump Turn into More Strength?

ViewRay, Inc. (VRAY) CEO Scott Drake on Q1 2021 Results - Earnings Call Transcript

The market liked the company's first-quarter update.

Why ViewRay Stock Vaulted Higher Today

The stock price of ViewRay, Inc. (Nasdaq: VRAY) increased by over 5% pre-market. This is why it happened.

VRAY Stock: Over 5% Increase Pre-Market Explanation

CLEVELAND, May 6, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the first quarter ended March 31, 2021. First Quarter 2021 Highlights Received seven new orders for MRIdian systems totaling $40.9 million, compared to four new orders totaling $22.6 million in the first quarter of 2020.

ViewRay Reports First Quarter 2021 Results

ViewRay (VRAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ViewRay (VRAY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

CLEVELAND, April 19, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its first quarter 2021 financial results. ViewRay will hold a conference call to discuss results on Thursday, May 6, 2021 at 4:30 p.m.

News for ViewRay Stock (VRAY)